Protagenic Therapeutics (NASDAQ:PTIX) is a biotechnology firm focused on developing innovative treatments aimed at modulating the body's stress response system to address central nervous system disorders, including anxiety, depression, and substance dependence. Their work revolves around leveraging the therapeutic potential of natural brain peptides to create novel, first-in-class medications. A key project in their pipeline is the development of PT00114, a proprietary peptide designed to target and regulate the stress response pathway at its core, offering a new approach to treating a range of psychiatric and neurological conditions. Through its research and development efforts, Protagenic Therapeutics aims to revolutionize the understanding and treatment of mental health disorders, striving to improve patient outcomes and quality of life.